Scholar Rock has won regulatory approval in the US for apitegromab (Isembyld), the first muscle-targeted therapy for spinal muscular atrophy (SMA), for patients aged 2 years and older who are already receiving an SMN2-directed therapy such as nusinersen, risdiplam or onasemnogene abeparvovec. Rather than repairing the SMN gene defect, apitegromab binds promyostatin and latent myostatin in skeletal muscle to block mature myostatin signalling, unlocking muscle growth downstream of motor-neuron protection.

The approval is anchored by the Phase III SAPPHIRE trial in 188 patients aged 2 to 21 years, where the 10 mg/kg every-four-weeks arm added 2.2 HFMSE points in motor function over placebo (p=0.0121) and lifted the share of patients gaining at least 3 HFMSE points to 34.2% versus 13.5%.

The commercial logic is additive, not substitutional: existing SMA standards fix the neuronal cause but do not reverse established muscle atrophy, so apitegromab slots in as a complimentary franchise that Biogen, Roche and Novartis cannot easily displace without their own myostatin or activin programmes. Scholar Rock also frames apitegromab beyond rare disease, with Phase II proof of concept in GLP-1-associated lean-mass loss positioning the antibody in the broader muscle-preservation and metabolic-wellness market.